# Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above

> **NCT07354659** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 800 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** A zoster mRNA vaccine SYS6017
- **OTHER:** Placebo
- **BIOLOGICAL:** Active Comparator Vaccine

## Key facts

- **NCT ID:** NCT07354659
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-10
- **Primary completion:** 2027-03-10
- **Final completion:** 2027-05-31
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07354659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07354659, "Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07354659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*